Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy

Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy

Background/AimsChimeric antigen receptor (CAR) T cells for refractory or relapsed (r/r) B-cell acute lymphoblastic leukemia (ALL) patients have shown promising clinical effectiveness. However, the factors impacting the clinical response of CAR-T therapy have not been fully elucidated. We here aimed...

Full description

Bibliographic Details
Main Authors: Jingxian Gu, Sining Liu, Wei Cui, Haiping Dai, Qingya Cui, Jia Yin, Zheng Li, Liqing Kang, Huiying Qiu, Yue Han, Miao Miao, Suning Chen, Shengli Xue, Ying Wang, Zhengming Jin, Xiaming Zhu, Lei Yu, Depei Wu, Xiaowen Tang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Immunology
Subjects:
chimeric antigen receptor T cells
refractory or relapsed B-cell acute lymphoblastic leukemia
predictive models
complete remission
MRD-negative complete remission
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.858590/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.858590/full

Similar Items